352 related articles for article (PubMed ID: 27432877)
41. Amyloidosis and Waldenström's macroglobulinemia.
Gertz MA; Merlini G; Treon SP
Hematology Am Soc Hematol Educ Program; 2004; ():257-82. PubMed ID: 15561687
[TBL] [Abstract][Full Text] [Related]
42. Future Directions in the Frontline Management of Waldenström Macroglobulinemia.
Buske C; Palomba ML
Hematol Oncol Clin North Am; 2023 Aug; 37(4):719-725. PubMed ID: 37270384
[TBL] [Abstract][Full Text] [Related]
43. Bortezomib and Waldenstrom's macroglobulinemia.
Pascal L; Gay J; Willekens C; Wemeau M; Balkaran S; Robu D; Roccaro A; Morel P; Ghobrial I; Leleu X
Expert Opin Pharmacother; 2009 Apr; 10(5):909-16. PubMed ID: 19351237
[TBL] [Abstract][Full Text] [Related]
44. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Buske C; Sadullah S; Kastritis E; Tedeschi A; García-Sanz R; Bolkun L; Leleu X; Willenbacher W; Hájek R; Minnema MC; Cheng M; Bilotti E; Graef T; Dimopoulos MA;
Lancet Haematol; 2018 Jul; 5(7):e299-e309. PubMed ID: 29958569
[TBL] [Abstract][Full Text] [Related]
45. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
46. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
Merchionne F; Procaccio P; Dammacco F
Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
[TBL] [Abstract][Full Text] [Related]
47. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
48. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
49. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.
Sacco A; Aujay M; Morgan B; Azab AK; Maiso P; Liu Y; Zhang Y; Azab F; Ngo HT; Issa GC; Quang P; Roccaro AM; Ghobrial IM
Clin Cancer Res; 2011 Apr; 17(7):1753-64. PubMed ID: 21355079
[TBL] [Abstract][Full Text] [Related]
50. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Ilizaliturri F; Huff CA; Kassim A; Krishnan AY; Medeiros BC; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Tricot G; Weber DM; Yahalom J; Yunus F; Kumar R; Shead DA;
J Natl Compr Canc Netw; 2012 Oct; 10(10):1211-9. PubMed ID: 23054875
[TBL] [Abstract][Full Text] [Related]
51. [New developments in Waldenström's macroglobulinemia].
Grunenberg A; Buske C
Dtsch Med Wochenschr; 2016 Feb; 141(3):170-2. PubMed ID: 26841176
[TBL] [Abstract][Full Text] [Related]
52. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
[TBL] [Abstract][Full Text] [Related]
53. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
Mailankody S; Landgren O
Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
[TBL] [Abstract][Full Text] [Related]
54. Proteasome Inhibitors in Waldenström Macroglobulinemia.
Kastritis E; Dimopoulos MA
Hematol Oncol Clin North Am; 2018 Oct; 32(5):829-840. PubMed ID: 30190021
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics-Pharmacodynamics Modeling and Evaluation of Tumor Response to Bortezomib Proteasome Inhibitor in Waldenstrom Macroglobulinemia.
Munir A; Fazal S; Bhatti AI; Sajjad B
Am J Clin Oncol; 2023 Apr; 46(4):150-160. PubMed ID: 36808095
[TBL] [Abstract][Full Text] [Related]
56. Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.
Cingam S; Sidana S
Blood Lymphat Cancer; 2022; 12():107-117. PubMed ID: 36003901
[TBL] [Abstract][Full Text] [Related]
57. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.
Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595
[TBL] [Abstract][Full Text] [Related]
58. Waldenström macroglobulinemia: from biology to treatment.
Sahin I; Leblebjian H; Treon SP; Ghobrial IM
Expert Rev Hematol; 2014 Feb; 7(1):157-68. PubMed ID: 24405328
[TBL] [Abstract][Full Text] [Related]
59. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
60. [Waldenström's macroglobulinemia].
Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
